Teva Pharmaceutical Indus TEVA has outperformed the market over the past 5 years by 2.65% on an annualized basis producing an average annual return of 15.91%. Currently, Teva Pharmaceutical Indus ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update ...

Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Twin Momentum Investor model based ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $30.00. The company’s shares ...

Learn more › You likely know Teva best for its extensive sandals, which it has been making since the mid-’80s. Now, the company has released its first truly winterized hiking boots ...

TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9%, respectively. Teva reported earnings before trading ...

JSW MG Motor India has unveiled two new cars at the Bharat Mobility Global Expo 2025. Introducing the MG Cyberster, India’s first all-electric roadster, and the MG M9, the country’s first ...

MG University Result 2025: Mahatma Gandhi University (MGU) Nalgonda has recently declared the semester results for various courses like BA, BSc, BCom, LLB, and other exams. Mahatma Gandhi ...

Expected to be priced from Rs 46 lakh (ex-showroom). The MG Majestor has been revealed at the Bharat Mobility Global Expo 2025 as the carmaker's flagship SUV in India. The MG Majestor gets ...

The M9 positions MG in the premium electric MPV segment and will be offered exclusively through the brand's 'Select' dealerships MG to retail the premium M9 MPV via its new ‘Select’ dealerships.

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.